News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer
Photo of Daniel P. Petrylak from medicine.yale.edu
Sep 15, 2024, 16:36

Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer

Eda Eylemer Mocan, Medical oncologist at Ankara university, shared a recent article by Daniel P. Petrylak on X:

“TROPHY-U-01 Cohort 2
SG in Metastatic Urothelial Cancer

  • Cisplatin-Ineligible
  • Progressing after ICI
  • Med f/u 9.3 m, ORR 32%, DOR 5.6 m
  • Grade ≥3 AE 87% of pts
  • Neutropenia 34%
  • Anemia 24%
  • Fatigue 18%
  • Diarrhea 16%

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Authors: Daniel P. Petrylak, MD, Scott T. Tagawa, MD, Rohit K. Jain, MD, Manojkumar Bupathi, MD, Arjun Balar, MD,Arash Rezazadeh Kalebasty, MD, Saby George, MD and Petros Grivas, MD, PhD

Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer

Source: Eda Eylmer Mocan/X

anemia cancer diarrhea Eda Eylemer Mocan neutropenia OncoDaily Oncology Sacituzumab govitecan
Special Coverage
Insight
Nov 12, 2024, 18:59
Dana-Farber’s Breast Cancer Research Digest
Insight
Nov 12, 2024, 18:58
Erman Akkus: First-line chemotherapies in advanced pancreatic cancer
Insight
Nov 12, 2024, 18:55
Jayant Gadrey: Analysis of ongoing clinical trials of ADCs for patients with breast cancer brain metastases
Insight
Nov 12, 2024, 18:55
María Natalia Gandur Quiroga: Just cast my vote for the ASCO election
Insight
Nov 12, 2024, 18:49
Vivek Subbiah: Our latest publication on pancreatic cancer management with tumor-agnostic precision medicine
Insight
Nov 12, 2024, 18:46
Neeraj Agarwal: Changing the diagnostic paradigm of ccRCC
Blog
Nov 12, 2024, 18:44
Bruna David: Leadership and Strategy Training for Healthcare Professionals by ESO, ECO, and SPCC
Insight
Nov 12, 2024, 18:43
Paolo Tarantino: Could ADCs be safely administered subcutaneously?
Insight
Nov 12, 2024, 18:35
Jean-Charles Soria: ecDNA fuels cancer progression
Blog
Nov 12, 2024, 18:35
Venous thromboembolism associated mortality in ALK-positive non-small cell lung cancer
Blog
Nov 12, 2024, 18:33
Shilpy Sharma Calls for Systematic Revamp in Manuscript Review
Blog
Nov 12, 2024, 18:30
Common lung cancer symptoms by Florez Lab